BioLineRx Ltd.
BLRX
$3.22
$0.21797.26%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 28.94M | 21.99M | 17.05M | 11.66M | 4.80M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 28.94M | 21.99M | 17.05M | 11.66M | 4.80M |
| Cost of Revenue | 9.26M | 6.87M | 6.04M | 5.15M | 3.69M |
| Gross Profit | 19.68M | 15.13M | 11.00M | 6.51M | 1.11M |
| SG&A Expenses | 29.68M | 32.58M | 35.27M | 34.14M | 31.58M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 48.09M | 49.84M | 51.86M | 50.61M | 47.79M |
| Operating Income | -19.15M | -27.85M | -34.82M | -38.96M | -42.99M |
| Income Before Tax | -9.22M | -19.92M | -30.12M | -49.15M | -60.61M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -9.22 | -19.92 | -30.12 | -49.15 | -60.61 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -9.22M | -19.92M | -30.12M | -49.15M | -60.61M |
| EBIT | -19.15M | -27.85M | -34.82M | -38.96M | -42.99M |
| EBITDA | -15.70M | -24.99M | -32.57M | -36.99M | -41.67M |
| EPS Basic | -0.01 | -0.02 | -0.03 | -0.05 | -0.06 |
| Normalized Basic EPS | 0.00 | -0.01 | -0.02 | -0.03 | -0.04 |
| EPS Diluted | -0.01 | -0.02 | -0.03 | -0.05 | -0.06 |
| Normalized Diluted EPS | 0.00 | -0.01 | -0.02 | -0.03 | -0.04 |
| Average Basic Shares Outstanding | 4.79B | 4.56B | 4.29B | 4.02B | 3.85B |
| Average Diluted Shares Outstanding | 4.79B | 4.56B | 4.29B | 4.02B | 3.85B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |